Trillium Therapeutics surged 1,330% last year – and as an immuno-oncology company, its performance had nothing to do with COVID-19 related catalysts. Moreover, its 2020 run may have just been the beginning, as the company’s cancer-fighting candidates – which it hopes will ultimately replace chemotherapy as the dominant type of cancer treatment – are, as today’s article explains, currently in a league of their own. For more, CLICK HERE.
“In A League Of Its Own”: This Immuno-Oncology Stock’s Great Run In 2020 May Have Just Been The Beginning
